Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

A Randomized, Double-Blind Comparison of LY686017, Paroxetine, and Placebo in the Treatment of Social Anxiety Disorder

This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.

Inclusion Criteria:

• Male or female outpatients at least 18 years of age and not more than 65 years of age.
• Must sign the informed consent document.
• Present at Visit 1 with social anxiety disorder based on a Clinical Global Impression-Severity score of greater than or equal to 4.
• Females of childbearing potential (not surgically sterilized and between menarche and 1 year post-menopause) must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use both a reliable primary method of birth control.
• Judged to be reliable and willing to keep all appointments for clinic visits, tests, and procedures required by the protocol.

Exclusion Criteria:

• Have any comorbid Axis I disorders (such as major depression, obsessive compulsive disorder, post-traumatic stress disorder, or panic disorder), in the opinion of the investigator, if the disorder occurred within the last 6 months.
• Have had any previous or current diagnoses of bipolar disorders, schizophrenia, or other psychotic disorders.
• Have the presence of an Axis II disorder, except avoidant personality disorder.
• Have a serious medical illness.
• Have abnormal thyroid-stimulating hormone (TSH) concentrations or are taking thyroid supplements.